Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Fibroblast-specific TGF-β–Smad2/3 signaling underlies cardiac fibrosis
Hadi Khalil, … , Jason Karch, Jeffery D. Molkentin
Hadi Khalil, … , Jason Karch, Jeffery D. Molkentin
Published September 11, 2017
Citation Information: J Clin Invest. 2017;127(10):3770-3783. https://doi.org/10.1172/JCI94753.
View: Text | PDF
Research Article Cardiology Cell biology

Fibroblast-specific TGF-β–Smad2/3 signaling underlies cardiac fibrosis

  • Text
  • PDF
Abstract

The master cytokine TGF-β mediates tissue fibrosis associated with inflammation and tissue injury. TGF-β induces fibroblast activation and differentiation into myofibroblasts that secrete extracellular matrix proteins. Canonical TGF-β signaling mobilizes Smad2 and Smad3 transcription factors that control fibrosis by promoting gene expression. However, the importance of TGF-β–Smad2/3 signaling in fibroblast-mediated cardiac fibrosis has not been directly evaluated in vivo. Here, we examined pressure overload–induced cardiac fibrosis in fibroblast- and myofibroblast-specific inducible Cre-expressing mouse lines with selective deletion of the TGF-β receptors Tgfbr1/2, Smad2, or Smad3. Fibroblast-specific deletion of Tgfbr1/2 or Smad3, but not Smad2, markedly reduced the pressure overload–induced fibrotic response as well as fibrosis mediated by a heart-specific, latency-resistant TGF-β mutant transgene. Interestingly, cardiac fibroblast–specific deletion of Tgfbr1/2, but not Smad2/3, attenuated the cardiac hypertrophic response to pressure overload stimulation. Mechanistically, loss of Smad2/3 from tissue-resident fibroblasts attenuated injury-induced cellular expansion within the heart and the expression of fibrosis-mediating genes. Deletion of Smad2/3 or Tgfbr1/2 from cardiac fibroblasts similarly inhibited the gene program for fibrosis and extracellular matrix remodeling, although deletion of Tgfbr1/2 uniquely altered expression of an array of regulatory genes involved in cardiomyocyte homeostasis and disease compensation. These findings implicate TGF-β–Smad2/3 signaling in activated tissue-resident cardiac fibroblasts as principal mediators of the fibrotic response.

Authors

Hadi Khalil, Onur Kanisicak, Vikram Prasad, Robert N. Correll, Xing Fu, Tobias Schips, Ronald J. Vagnozzi, Ruijie Liu, Thanh Huynh, Se-Jin Lee, Jason Karch, Jeffery D. Molkentin

×

Figure 4

Fibroblast-specific Smad2/3 deletion alters myofibroblast activity in vivo.

Options: View larger image (or click on image) Download as PowerPoint
Fibroblast-specific Smad2/3 deletion alters myofibroblast activity in vi...
(A) Experimental scheme whereby mice were subjected to TAC for 4 weeks. Mice were fed tamoxifen-laden chow 48 hours before surgery and then until harvesting. (B and C) Representative immunostaining images and quantitation for EGFP+ cellular expression (green) and costaining for αSMA (red) and DAPI (blue) in isolated cardiac interstitial cells from the indicated genotypes of mice that were cultured for 96 hours in low serum medium. The white arrows indicate EGFP+ cells and the yellow arrow shows EGFP– cells that are αSMA+ (n = 4). *P < 0.05 versus PostnMCM/+ R26EGFP/+ cells. P values were calculated with Student’s t test. Scale bars: 10 μm. (D and E) Representative immunohistochemistry cryosections and quantitation of EGFP-labeled (green) interstitial cells along with αSMA (red) staining from hearts of the indicated genotypes of mice after 4 weeks of TAC. The white arrows show EGFP+ cells that are also αSMA+ in each of the 2 genotypes of mice, although in the Smad2/3-deleted hearts, most of the EGFP+ fibroblasts are deficient in αSMA expression (n = 4 mice in each group). *P < 0.05 versus PostnMCM R26EGFP hearts. P values were calculated with Student’s t test. Scale bars: 10 μm. Additional images of immunohistochemistry as shown in D are shown in Supplemental Figure 5.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts